Clinical Trial

Irinotecan Plus Anlotinib or Further in Combination With Penpulimab for Second-line Treatment of mCRC

Unknown Phase 2
View on ClinicalTrials.gov →
Record status
This record was last updated July 3, 2024 (before its estimated May 31, 2025 completion). Its status may not reflect the trial's current state.
Summary
This is an exploratory, non-controlled, multi-cohort, phase II small-sample clinical study designed to evaluate the clinical benefit of second-line treatment with anlotinib plus irinotecan or further in combination with a PD-1 monoclonal antibody (penpulimab) in patients with advanced colorectal cancer after first-line treatment failure. To explore the rationality of the combination of chemotherapy and targeted therapy and immunotherapy strategy and obtain relevant survival and safety data. The study will fully evaluate the efficacy, PFS, OS, safety and related biomarkers of the regimen.
Protocol Amendment History 1 change
critical Trial status changed: Recruiting → Unknown 2026-08-02
Trial Details
NCT Number NCT05229003
Lead Sponsor Fudan University
Conditions Metastatic Colorectal Cancer
Enrollment 44 participants
Start Date 2022-03-09
Primary Completion 2025-05-31 (estimated)
Study Completion 2025-12-31 (estimated)
Updated on ClinicalTrials.gov 2024-07-03